Massachusetts' AVROBIO Awarded Johnson & Johnson Coveted J-Labs Incubator Space
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
AVROBIO, a clinical-stage biotechnology company developing transformative, life-changing gene therapies targeting rare diseases and cancer, today announced it has been awarded lab space at Johnson & Johnson’s (J&J) newest JLABS facility in Toronto, Ontario. AVROBIO, headquartered in Cambridge, MA with researchers in Toronto, will join other early stage companies in the 40,000 square foot facility opening this spring.
“It’s an honor to be selected from a talented pool of companies and to co-locate amongst top scientists within innovative, emerging companies,” said Geoff MacKay, President & Chief Executive Officer of AVROBIO.
JLABS incubator space was launched by J&J Innovation in collaboration with the Ontario Government, University of Toronto and MaRS Discovery District (MaRS). The newest facility in Toronto joins J&J’s existing centers of JLABS located in Boston, San Diego, San Francisco, and Houston.
JLABS provides early-stage companies with access to core research facilities hosting specialized capital equipment. The final step in the month long process which began with 64 applicants culminated in a presentation to worldwide senior J&J leadership members, Ontario government officials and the media.
About AVROBIO
AVROBIO is a clinical stage company developing transformative gene therapies targeting rare diseases and cancer. The catalyst for creating AVROBIO is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to treat serious debilitating disease resulting in durable patient outcomes. A unifying theme across our portfolio is the expert design and manufacturing of optimal cell and gene delivery systems. AVROBIO has offices in both Cambridge, MA and Toronto, ON. More information is available at www.avrobio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160513005043/en/
- Board & Management Changes